Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Cytosine methylation WP3585,0.0004869782857390216,88.76271186440678,677.0190354409403,"['TDG', 'TET1']",0.026783805715646185,0,0,2
2,Macrophage markers WP4146,0.017265256058615744,87.3,354.3558609288562,['CD74'],0.3492090923606442,0,0,1
3,Cytokines and Inflammatory Response WP530,0.028612234105849635,43.641666666666666,155.09903069633694,['PDGFA'],0.3492090923606442,0,0,1
4,16p11.2 proximal deletion syndrome WP4949,0.04022297975677588,6.667732651103294,21.42553741863002,"['SIAH1', 'CCDC6']",0.3492090923606442,0,0,2
5,Mesodermal commitment pathway WP2857,0.08670708588160807,4.245456401878701,10.38107350113932,"['CCDC6', 'TET1']",0.3492090923606442,0,0,2
6,Hair Follicle Development: Organogenesis - Part 2 of 3 WP2839,0.08875499163349868,11.625555555555556,28.155649434686215,['PDGFA'],0.3492090923606442,0,0,1
7,DNA Repair Pathways Full Network WP4946,0.09197228667274124,4.096176586519511,9.774575025275764,"['TDG', 'RAD23B']",0.3492090923606442,0,0,2
8,miRNA regulation of p53 pathway in prostate cancer WP3982,0.09403731115573583,10.897916666666667,25.763368633631924,['SIAH1'],0.3492090923606442,0,0,1
9,Fluoropyrimidine Activity WP1601,0.09928950940204052,10.255882352941176,23.68816899078755,['TDG'],0.3492090923606442,0,0,1
10,Sphingolipid pathway WP1422,0.10451175522833037,9.685185185185185,21.873561916387693,['GBA2'],0.3492090923606442,0,0,1
11,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.10451175522833037,9.685185185185185,21.873561916387693,['FOXO4'],0.3492090923606442,0,0,1
12,Differentiation Pathway WP2848,0.10451175522833037,9.685185185185185,21.873561916387693,['PDGFA'],0.3492090923606442,0,0,1
13,Extracellular vesicle-mediated signaling in recipient cells WP2870,0.11486706058724883,8.715,18.859084080664516,['MFGE8'],0.3492090923606442,0,0,1
14,Lung fibrosis WP3624,0.12000045325554695,8.299206349206349,17.596473254504094,['PDGFA'],0.3492090923606442,0,0,1
15,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities WP3844,0.12000045325554695,8.299206349206349,17.596473254504094,['FOXO4'],0.3492090923606442,0,0,1
16,Tumor suppressor activity of SMARCB1 WP4204,0.12510455984760105,7.921212121212121,16.46507438912744,['ACTL6B'],0.3492090923606442,0,0,1
17,Base Excision Repair WP4752,0.13522557099734414,7.259722222222222,14.525332069447533,['TDG'],0.3492090923606442,0,0,1
18,Phosphoinositides metabolism WP4971,0.13522557099734414,7.259722222222222,14.525332069447533,['SACM1L'],0.3492090923606442,0,0,1
19,Neural Crest Cell Migration during Development WP4564,0.1402428014464545,6.968666666666667,13.689109862079972,['EPHB3'],0.3492090923606442,0,0,1
20,miRNA regulation of prostate cancer signaling pathways WP3981,0.1402428014464545,6.968666666666667,13.689109862079972,['PDGFA'],0.3492090923606442,0,0,1
21,Ras signaling WP4223,0.1469557471365842,3.0546794399410464,5.85772592640309,"['GNB4', 'FOXO4']",0.3492090923606442,0,0,2
22,Neural Crest Cell Migration in Cancer WP4565,0.15019152007263392,6.451234567901235,12.230534340524308,['EPHB3'],0.3492090923606442,0,0,1
23,Amyotrophic lateral sclerosis (ALS) WP2447,0.16002698260470455,6.005172413793104,11.003955017554635,['NEFH'],0.3492090923606442,0,0,1
24,Eukaryotic Transcription Initiation WP405,0.1745705911772402,5.440625,9.496208794652338,['GTF2E1'],0.3492090923606442,0,0,1
25,PDGF Pathway WP2526,0.1745705911772402,5.440625,9.496208794652338,['PDGFA'],0.3492090923606442,0,0,1
26,Glucocorticoid Receptor Pathway WP2880,0.1745705911772402,5.440625,9.496208794652338,['MFGE8'],0.3492090923606442,0,0,1
27,Modulators of TCR signaling and T cell activation WP5072,0.1745705911772402,5.440625,9.496208794652338,['ZFP36L1'],0.3492090923606442,0,0,1
28,Nucleotide Excision Repair WP4753,0.18412843051743055,5.1196078431372545,8.662999900152178,['RAD23B'],0.3492090923606442,0,0,1
29,Rett syndrome causing genes WP4312,0.18412843051743055,5.1196078431372545,8.662999900152178,['ACTL6B'],0.3492090923606442,0,0,1
30,MECP2 and Associated Rett Syndrome WP3584,0.22128313126341176,4.141269841269842,6.246328075549805,['TET1'],0.38001317024757225,0,0,1
31,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.22580882302301744,4.044573643410852,6.018594762032083,['NEFH'],0.38001317024757225,0,0,1
32,Nuclear Receptors Meta-Pathway WP2882,0.22819567561124018,2.272507153863086,3.357747016905738,"['MFGE8', 'SLC5A3']",0.38001317024757225,0,0,2
33,AGE/RAGE pathway WP2324,0.23478273178596978,3.864074074074074,5.599409408313277,['FOXO4'],0.38001317024757225,0,0,1
34,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.23923123896038614,3.7797101449275363,5.406212657319127,['SIAH1'],0.38001317024757225,0,0,1
35,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.2582494374177218,2.080306698950767,2.816380264845684,"['GNB4', 'PDGFA']",0.38001317024757225,0,0,2
36,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.26109503315857985,3.407516339869281,4.575854282655691,['ACTL6B'],0.38001317024757225,0,0,1
37,Retinoblastoma gene in cancer WP2446,0.26109503315857985,3.407516339869281,4.575854282655691,['CCDC6'],0.38001317024757225,0,0,1
38,PI3K-Akt signaling pathway WP4172,0.2625545539892317,2.05543369890329,2.7487240732838756,"['GNB4', 'PDGFA']",0.38001317024757225,0,0,2
39,Glioblastoma signaling pathways WP2261,0.29479813896346224,2.9432203389830507,3.5950389583271622,['FOXO4'],0.4109919410197197,0,0,1
40,Androgen receptor signaling pathway WP138,0.29890322983252343,2.8938888888888887,3.4947626775258147,['RNF4'],0.4109919410197197,0,0,1
41,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.3110779896925274,2.755291005291005,3.217385344093631,['PDGFA'],0.4172997422704636,0,0,1
42,Ebola Virus Pathway on Host WP4217,0.3190787169462648,2.67,3.049987578285872,['MFGE8'],0.417841176953442,0,0,1
43,Thermogenesis WP4321,0.3309087354803021,2.551470588235294,2.8217036385379064,['ACTL6B'],0.41850871075711804,0,0,1
44,NRF2 pathway WP2884,0.3348069686056944,2.5142512077294685,2.7510965034218637,['SLC5A3'],0.41850871075711804,0,0,1
45,ESC Pluripotency Pathways WP3931,0.34253653598615863,2.442957746478873,2.617328625648114,['PDGFA'],0.41865576620530504,0,0,1
46,Metapathway biotransformation Phase I and II WP702,0.3539655183949525,2.343243243243243,2.4335888054444688,['KCNAB3'],0.42321964155918235,0,0,1
47,Endoderm differentiation WP2853,0.36890066036413083,2.2222222222222223,2.2160619650917766,['TET1'],0.4316922621282382,0,0,1
48,Chemokine signaling pathway WP3929,0.39422423253529876,2.037843137254902,1.8968965592345146,['GNB4'],0.45171526644669646,0,0,1
49,Regulation of Actin Cytoskeleton WP51,0.41854766353131917,1.8815217391304349,1.6387386486341406,['PDGFA'],0.4697983978412766,0,0,1
50,Calcium Regulation in the Cardiac Cell WP536,0.43533080091745396,1.7836769759450173,1.4833933071771372,['GNB4'],0.4788638810091994,0,0,1
51,Myometrial relaxation and contraction pathways WP289,0.44517099823869427,1.7296666666666667,1.3998137069136334,['GNB4'],0.4800863706495722,0,0,1
52,EGF/EGFR signaling pathway WP437,0.5065953682257234,1.438611111111111,0.9783169616913163,['FOXO4'],0.5283544905476335,0,0,1
53,VEGFA-VEGFR2 Signaling Pathway WP3888,0.509141599982265,1.1866736560079212,0.8010392602383789,"['FLII', 'FOXO4']",0.5283544905476335,0,0,2
54,Focal Adhesion WP306,0.5292466932881102,1.34765625,0.8575145032537291,['PDGFA'],0.5390475579786308,0,0,1
55,MAPK Signaling Pathway WP382,0.6236158207575396,1.0353413654618473,0.4889096989641074,['PDGFA'],0.6236158207575396,0,0,1
